Since MVP represents another progressive condition often occurring in Marfan patients, especially when carrying FBN1 mutation with respect to TGFBR2 mutation, the potential impact of angiotensin receptor inhibition on MVP development and progression would represent an interesting area of investigation of dedicated studies. The gene discussed is TGFBR2; the disease is familial mitral valve prolapse.